{"brief_title": "A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma", "brief_summary": "For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma", "condition": "Non-Hodgkin's Lymphoma", "intervention_type": "Drug", "intervention_name": "Topotecan", "criteria": "INCLUSION: - Bidimensionally measurable current/refractory aggressive NHL (Diffuse lg cell, diffuse mixed cell, follicular lg non-cleaved, immunoblastic, Ki-1+ALCL, peripheral T-cell lymphoma, mantle cell lymphoma & transformed lymphoma.) - No more than 3 prior treatment regimens. No anti-lymphoma therapy within the past 3 weeks. - Not be eligible for treatment of a higher priority. - Performance status <2 Zubrod, > 60 Karnofsky. - Good marrow reserve: ANC>1.5 x 10(9)/L, platelets > 100 x 10(9)/L. - Bilirubin <1.5mg/dL, SGOT, SGPT < 2 x normal values. - Serum creatinine < 1.8 mg/dL. - Age > 18 yrs. - Signed informed consent. - Life expectancy of > 12 weeks. - No prior Taxane (paclitaxel or docetaxel), topotecan, or CPT-11. - No prior stem cell or bone marrow transplantation. - No prior second malignancies except for basal cell carcinoma of the skin. EXCLUSION: - Active or prior history of CNS lymphoma. - Serious intercurrent medical illnesses requiring hospitalization. - History of primary/secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on a functional immune system) or patients taking immunosuppressive drugs (systemic corticosteroids). - Prior exposure to Filgrastim-SD/01. - Women who are pregnant or lactating. - Participation in another clinical trial. - Positive HIV antibody. - History of prior sensitivity to E. coli derived products (such as filgrastim/neupogen).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00038545.xml"}